Denali Therapeutics Inc.

Informe acción NasdaqGS:DNLI

Capitalización de mercado: US$3.0b

Denali Therapeutics Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Denali Therapeutics de 38.4% y 52.7% por año respectivamente. Se prevé que el BPA crezca en un 40.4% al año. Se espera que la rentabilidad financiera sea de -64.2% en 3 años.

Información clave

38.4%

Tasa de crecimiento de los beneficios

40.40%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs25.5%
Tasa de crecimiento de los ingresos52.7%
Rentabilidad financiera futura-64.18%
Cobertura de analistas

Good

Última actualización14 May 2026

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Seeking Alpha • May 03

Denali: The First Commercial Validation Of The Blood-Brain Barrier Platform

Summary Denali Therapeutics has transitioned from a speculative platform to a commercial-stage rare disease company with FDA approval of AVLAYAH for Hunter syndrome. DNLI’s TransportVehicle technology enables delivery of biologics across the blood-brain barrier, providing significant differentiation and commercial potential in neurodegenerative and lysosomal storage diseases. With $1.17 billion in pro-forma liquidity and a focused initial launch, DNLI is positioned for 2.8 years of runway, reducing near-term capital risk. While valuation appears high on sales multiples, DNLI’s now-validated platform and pipeline optionality make the current price/book premium reasonable for early-stage commercial growth. Read the full article on Seeking Alpha
Artículo de análisis • May 08

We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Mar 20

Denali Therapeutics: Vast Pipeline, First Approval Up Ahead

Summary Denali Therapeutics' stock has significantly dropped from $100 to $15 since 2021, but the company is now heavily derisked with promising product candidates nearing key milestones. Lead asset DNL310 shows strong biomarker data for Hunter syndrome, with plans for a BLA submission and accelerated approval by Q2 2025. The Biogen partnership for Parkinson’s Disease asset DNL151 includes substantial milestone payments and profit-sharing, highlighting its potential impact. Despite past failures, Denali's extensive pipeline and solid financial runway make it a compelling buy at current low stock prices. Read the full article on Seeking Alpha
Seeking Alpha • Jan 09

Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains

Summary Denali Therapeutics Inc.'s DNL343 failed to meet the primary endpoint in the phase 2/3 HEALY ALS trial, but potential biomarker analyses in 2025 may offer a path forward. Despite the trial setback in ALS, Denali's stock remains stable due to continued pre-specified analyses expected in late 2025. BLA filing of tividenofusp alfa for the treatment of patients with MPS II remains on track under the Accelerated Approval Pathway Program in early 2025. Financially, Denali has $1.28 billion in cash but may need additional funding in 2025, posing a risk of shareholder dilution. Read the full article on Seeking Alpha
Artículo de análisis • Dec 09

We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Aug 20

Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology

Summary Denali Therapeutics' proprietary Transport Vehicle technology enables drug delivery across the blood-brain barrier, targeting neurodegenerative diseases. DNL310, targeting MPS II, and DNL343 for ALS are key drug candidates with potential, though competition is significant. The company’s $500 million capital raise supports its aggressive R&D investment, providing a runway for developing its pipeline. Despite its promising platform, DNLI still has a relatively high cash burn and regulatory hurdles before achieving drug approval. Due to Denali's high-risk, long-term biotech development, I deem DNLI a DCA "buy" for investors who understand the inherent risks. Read the full article on Seeking Alpha
Artículo de análisis • Jul 26

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Artículo de análisis • May 23

Revenues Not Telling The Story For Denali Therapeutics Inc. (NASDAQ:DNLI) After Shares Rise 25%

Denali Therapeutics Inc. ( NASDAQ:DNLI ) shareholders would be excited to see that the share price has had a great...
Seeking Alpha • May 13

Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data

Summary Denali Therapeutics Inc.'s DNL-310 is currently being explored in an ongoing phase 2/3 COMPASS study for treatment of patients with MPS II; Enrollment completion expected in 2024. Denali is in talks with CDER division of FDA to seek for Accelerated Approval pathway for DNL-310 for the treatment of patients with MPS II. Biomarker and safety data from a phase 1/2 study, using DNL-126 for the treatment of patients with MPS IIIA, expected end of 2024. Another promising program from the pipeline is the development of DNL-343, which is being advanced in the phase 2/3 HEALEY ALS Platform trial for treatment of patients with amyotrophic lateral sclerosis. Read the full article on Seeking Alpha
Artículo de análisis • Apr 17

An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued

Key Insights Using the 2 Stage Free Cash Flow to Equity, Denali Therapeutics fair value estimate is US$30.71 Denali...
Artículo de análisis • Mar 21

Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Those holding Denali Therapeutics Inc. ( NASDAQ:DNLI ) shares would be relieved that the share price has rebounded 25...
Seeking Alpha • Mar 07

Denali: Leveraging Transport Vehicle Technology For Neurological Gains

Summary Denali's stock performance has been flat despite the biotech sector's 20% rise; recently raised $500 million in a PIPE. ALS trial failure with partner Sanofi pressured stock; Denali's focus is on transport vehicle (TV) technology and BBB crossing. Denali boasts a strong financial position with $1.53 billion in cash, extending operational runway significantly. Recommends "buy" based on Denali's innovative TV technology, financial health, and potential in neurological disorders despite biotech risks. Read the full article on Seeking Alpha
Artículo de análisis • Feb 21

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Artículo de análisis • Jan 26

Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet

Denali Therapeutics Inc.'s ( NASDAQ:DNLI ) price-to-sales (or "P/S") ratio of 7x might make it look like a buy right...
Artículo de análisis • Nov 20

We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Artículo de análisis • Oct 09

Investor Optimism Abounds Denali Therapeutics Inc. (NASDAQ:DNLI) But Growth Is Lacking

With a median price-to-sales (or "P/S") ratio of close to 10.4x in the Biotechs industry in the United States, you...
Artículo de análisis • Aug 22

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:DNLI - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/2028422-294-2618915
12/31/2027114-471-385-29519
12/31/202642-484-277-36518
3/31/2026N/A-508-419-412N/A
12/31/2025N/A-513-422-413N/A
9/30/2025N/A-499-411-398N/A
6/30/2025N/A-479-368-350N/A
3/31/2025N/A-454-384-366N/A
12/31/2024N/A-423-364-348N/A
9/30/2024N/A-427-376-363N/A
6/30/20241-420-402-391N/A
3/31/2024295-137-425-413N/A
12/31/2023331-145-371-358N/A
9/30/2023341-124-348-332N/A
6/30/2023343-128-321-302N/A
3/31/2023101-371-248-231N/A
12/31/2022108-326-263-245N/A
9/30/2022111-303-254-238N/A
6/30/2022112-284-234-222N/A
3/31/202283-286-243-233N/A
12/31/202149-291-220-211N/A
9/30/202135330361368N/A
6/30/202135756404410N/A
3/31/202134058415420N/A
12/31/202033671413416N/A
9/30/202024-228-150-145N/A
6/30/202028-216-183-176N/A
3/31/202026-215-193-176N/A
12/31/201927-198N/A-152N/A
9/30/2019148-66N/A-11N/A
6/30/2019135-55N/A-15N/A
3/31/2019133-52N/A-14N/A
12/31/2018129-36N/A50N/A
9/30/20183-137N/A-61N/A
6/30/20182-123N/A-49N/A
3/31/20181-91N/A-24N/A
12/31/2017N/A-88N/A-77N/A
9/30/2017N/A-85N/A-77N/A
6/30/2017N/A-93N/A-76N/A
3/31/2017N/A-90N/A-75N/A
12/31/2016N/A-87N/A-72N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que DNLI siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que DNLI siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que DNLI siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (52.7% al año) de DNLI crezcan más rápidamente que los del mercado US (11.6% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (52.7% al año) de DNLI crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: DNLI se prevé que no sea rentable en 3 años.

Descubre empresas en crecimiento

7D

1Y

7D

1Y

7D

1Y

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/05/21 23:16
Precio de las acciones al final del día2026/05/21 00:00
Beneficios2026/03/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Denali Therapeutics Inc. está cubierta por 31 analistas. 19 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
null nullBaird
Joel BeattyBaird
Charles MooreBaird